1129 |
Trans-catheter Valve Therapies: Aortic and Mitral |
Ted Feldman |
May. 13. 11 |
1128 |
Update on Left Main/Multivessel PCI: Lessons from SYNTAX, a View to EXCEL |
Roxana Mehran |
May. 13. 11 |
1127 |
Update on ACS/AMI: Have We Made Any Progress? What's Next? |
Huay Cheem Tan |
May. 13. 11 |
1126 |
The Landscape of Antiplatelet Agents: Which Drug, for Whom, and Why? |
Matthew Price |
May. 13. 11 |
1125 |
Standard vs. High-Dose Clopidogrel According to Platelet Function Testing after PCI: Results of the GRAVITAS Trial |
Matthew Price |
May. 12. 11 |
1124 |
Use of a Point-of-Care Platelet Function Assay to Improve the Prediction of Atherothrombotic Events after DES Implantation: ASAN-VerifyNow Registry |
Duk-Woo Park |
May. 12. 11 |
1123 |
Association between CYP2C19 Genotype and Adverse Clinical Outcomes among PCI Patients: A Meta-analysis |
Alan C. Yeung |
May. 12. 11 |
1122 |
Association of Cytochrome P450 2C19 Polymorphism with Clinical Efficacy of Clopidogrel in Patients Receiving Elective PCI |
Ki-Bae Seung |
May. 12. 11 |
1121 |
(HK): Present a Complex PCI and TAVI Case |
Michael Kang-Yin Lee |
May. 12. 11 |
1120 |
How We Treat DM Patient with LM in Korea and Improve Outcomes with These Challenging Procedures |
Bum-Kee Hong |
May. 12. 11 |